Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KAMADA LTDKMDA · Entity 5493 | Director | August 27, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KAMADA LTD
Report date August 27, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.29 | IndirectHeld by trustee | 26,500 |
Reported balance
After 2026-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-27 · Grant · Acquired 26,500 · Balance 26,500 F1: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F4: This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.45. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3: Held by trustee under the Company's 2011 Share Award Plan. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 | IndirectHeld by trustee | 30,000 |
Reported balance
After 2026-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-27 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F5: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.05. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3: Held by trustee under the Company's 2011 Share Award Plan. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.26 | IndirectHeld by trustee | 30,000 |
Reported balance
After 2026-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-27 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F6: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.42. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3: Held by trustee under the Company's 2011 Share Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026.
F2: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter.
F3: Held by trustee under the Company's 2011 Share Award Plan.
F4: This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.45. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.
F5: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.05. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.
F6: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.42. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Sep 29, 2026 13:27 UTC | KAMADA LTD KMDA · Entity 5493 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001213900-26-104374 · ownership.xml · derivative · entry 3 Asher-Topilsky Lilach · CIK 0002128355 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by trustee Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F6 · derivative.exercise_price: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.42. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2 · derivative.exercise_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F2 · derivative.expiration_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3 · ownership.nature: Held by trustee under the Company's 2011 Share Award Plan. Read SEC document |
| August 27, 2026 Filed Sep 29, 2026 13:27 UTC | KAMADA LTD KMDA · Entity 5493 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001213900-26-104374 · ownership.xml · derivative · entry 2 Asher-Topilsky Lilach · CIK 0002128355 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by trustee Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F5 · derivative.exercise_price: This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.05. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2 · derivative.exercise_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F2 · derivative.expiration_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3 · ownership.nature: Held by trustee under the Company's 2011 Share Award Plan. Read SEC document |
| August 27, 2026 Filed Sep 29, 2026 13:27 UTC | KAMADA LTD KMDA · Entity 5493 | GrantEmployee Stock Option (right to buy) · Derivative | 26,500 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001213900-26-104374 · ownership.xml · derivative · entry 1 Asher-Topilsky Lilach · CIK 0002128355 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by trustee Disclosed balance after: 26,500 Underlying: Ordinary Shares · 26,500 shares Expires not disclosed F1 · derivative.exercise_price: The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026. F4 · derivative.exercise_price: This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.45. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026. F2 · derivative.exercise_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F2 · derivative.expiration_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3 · ownership.nature: Held by trustee under the Company's 2011 Share Award Plan. Read SEC document |
| August 05, 2026 Filed Aug 6, 2026 11:00 UTC | KAMADA LTD KMDA · Entity 5493 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001213900-26-085902 · ownership.xml · derivative · entry 1 Asher-Topilsky Lilach · CIK 0002128355 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by trustee Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The exercise price presented in U.S. dollars represent a convenience conversion from NIS based on the exchange rate published by the Bank of Israel as of August 4, 2026. F2 · derivative.exercise_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F2 · derivative.expiration_date: The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter. F3 · ownership.nature: Held by trustee under the Company's 2011 Share Award Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.